We are live on ! Find out more
RAPP

Rapport Therapeutics
RAPP

55 hedge funds and large institutions have $582M invested in Rapport Therapeutics in 2024 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 11 increasing their positions, 7 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 10

57% more funds holding

Funds holding: 35 → 55 (+20)

57% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 7

3.29% more ownership

Funds ownership: 74.47% → 77.76% (+3.3%)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

2% less capital invested

Capital invested by funds: $593M → $582M (-$11.6M)

Holders
55
Holders Change
+20
Holders Change %
+57.14%
% of All Funds
0.79%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
30
Increased
11
Reduced
7
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$26.8M
2
BlackRock
BlackRock
New York
+$12.4M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$10.8M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$9.39M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$4.34M

Top Sellers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
-$8.14M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$6.73M
3
Millennium Management
Millennium Management
New York
-$2.72M
4
Citadel Advisors
Citadel Advisors
Florida
-$2.26M
5
SVCM
Saturn V Capital Management
Texas
-$1.63M
Name Holding Trade Value Shares
Change 		Change in
Stake
Legal & General Group
51
Legal & General Group
United Kingdom
$18.6K +$19.5K +909 New
California State Teachers Retirement System (CalSTRS)
52
California State Teachers Retirement System (CalSTRS)
California
$14K +$14.7K +685 New
AB
53
Amalgamated Bank
New York
$6K +$6.81K +317 New
TRCT
54
Tower Research Capital (TRC)
New York
$5.26K +$5.52K +257 New
SCM
55
Sterling Capital Management
North Carolina
$389 +$408 +19 New
AG
56
Artal Group
Luxembourg
– -$8.14M -350,000 Closed
Millennium Management
57
Millennium Management
New York
– -$2.72M -116,782 Closed
SVCM
58
Saturn V Capital Management
Texas
– -$1.63M -70,000 Closed
MIM
59
Monashee Investment Management
Massachusetts
– -$930K -40,000 Closed
Alyeska Investment Group
60
Alyeska Investment Group
Illinois
– -$808K -34,731 Closed
SFM
61
Soros Fund Management
New York
– -$698K -30,000 Closed
Squarepoint
62
Squarepoint
New York
– -$380K -16,345 Closed
Two Sigma Investments
63
Two Sigma Investments
New York
– -$302K -13,000 Closed
Balyasny Asset Management
64
Balyasny Asset Management
Illinois
– -$233K -10,000 Closed
DKCM
65
Davidson Kempner Capital Management
New York
– -$229K -10,000 Closed
1 2
3

RAPP Hedge Fund Activity: Q3 2024 in Review

55 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Rapport Therapeutics (RAPP) for Q3 2024, worth a combined $582M — down 1.9% from $593M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new RAPP positions and 10 closed out — a net gain of 20 holders — while 11 added to existing stakes and 7 trimmed.

The largest buyer was Goldman Sachs, opening a new position worth an estimated $26.8M. The largest seller was Artal Group, exiting entirely with an estimated $8.14M sold.

  • 55 institutional investors held Rapport Therapeutics (RAPP) as of Q3 2024, up from 35 in Q2 2024.
  • Funds reported $582M of Rapport Therapeutics stock for Q3 2024, down 1.9% quarter-over-quarter.
  • 30 funds opened new Rapport Therapeutics positions in Q3 2024 and 10 closed out, a net change of +20 holders.
  • The largest Rapport Therapeutics buyer in Q3 2024 was Goldman Sachs, an estimated $26.8M added.
  • The largest Rapport Therapeutics seller in Q3 2024 was Artal Group, an estimated $8.14M sold.

Based on aggregated 13F filings for Q3 2024.